| Ytd | -1.95% | |
| 1y | 19.80% |
| Open | 293.11 | Prev Close | 293.61 | Low | 293.06 | High | 299.52 | Mkt Cap | 7.95B |
| Vol | 167.38K | Avg Vol | 380.35K | EPS | 6.00 | P/E | 49.52 | Forward P/E | 30.59 |
| Beta | 1.08 | Short Ratio | 3.09 | Inst. Own | 94.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 283.19 | 200-d Avg | 293.84 | 1yr Est | 297.00 |
BIO-key (BKYI) a global leader in biometric-powered identity & access management to participate at J
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signal
On June 25, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 6.5% to $298.29. This movement comes in
Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family
Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and t
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HI
https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-
RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and
U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the anal
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral
Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. T
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the anal
Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest f
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raise
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analys
Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025.
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnin
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fisc
During Friday, 125 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly
On Thursday, 1076 companies hit new 52-week lows.
On Monday, 429 stocks made new 52-week lows.
During Friday's session, 574 stocks hit new 52-week lows.
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings fo
During Wednesday's trading, 435 companies set new 52-week lows.
Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly ear
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
Tuesday's session saw 729 companies set new 52-week lows.
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly
Before 10 a.m. ET Friday, 183 stocks hit new 52-week highs.